Serotonin and the 5-HT2A Receptor
The primary receptor through which classical psychedelics act - how 5-HT2A activation in the prefrontal cortex triggers the cascade of perceptual and cognitive changes that define the psychedelic experience.
Serotonin is a neurotransmitter involved in the regulation of mood, appetite, sleep, and many other functions. The 5-HT2A receptor (5-hydroxytryptamine receptor 2A) is one of more than a dozen receptor subtypes that serotonin activates, and it is the receptor most directly implicated in the psychedelic experience. Classical psychedelics - psilocybin (via its active metabolite psilocin), LSD, DMT, mescaline, and others - all share the property of activating this receptor with high affinity.
The mechanism is not simply a matter of serotonin flooding the brain. In fact, serotonin levels themselves may not change significantly during a psychedelic experience. What changes is the pattern of receptor activation. 5-HT2A receptors are densely expressed in the prefrontal cortex, a region involved in executive function, self-monitoring, and abstract thought. When psychedelics activate these receptors, they trigger a cascade of intracellular signaling that produces the characteristic alterations in perception, cognition, and self-experience.
One key effect of 5-HT2A activation is the modulation of glutamate release. Glutamate is the brain's primary excitatory neurotransmitter. The activation of 5-HT2A receptors on certain interneurons leads to a complex pattern of disinhibition - the release of glutamate from neurons that are ordinarily suppressed. This glutamate release, particularly in the prefrontal cortex and thalamocortical circuits, is thought to be central to the unusual perceptual and cognitive effects of psychedelics.
The 5-HT2A receptor is also the target of blocking agents like ketanserin, which can terminate a psychedelic experience when administered during it. This pharmacological reversibility has been used in research settings to confirm the receptor's causal role, and it points toward potential medical applications if a rapid reversal of psychedelic effects were needed in a clinical context.
What the receptor biology cannot fully explain is the vast variation in psychedelic experiences between individuals, sessions, and settings. The same dose of the same substance acting on the same receptors can produce radically different experiences depending on the person's state of mind, history, and context. Pharmacology sets the range of possibilities; it does not determine the specific experience.